FDA Recalls Revolution Ink Golden Yellow Over Bacterial Contamination Risk

A 1-ounce bottle of Revolution Ink Golden Yellow is under recall after the FDA flagged it for contamination with Bacillus circulans, a bacterium capable of causing wound and soft-tissue infections once it bypasses the skin barrier. The implicated batch carries a production date of 8/22/2025 and an expiration of 8/22/2028. Revolution Ink operates out of Hesperia, California, and the recall was flagged as part of a broader FDA cosmetics monitoring digest published in late March.

The contamination risk is worth understanding clearly. Bacillus circulans belongs to a category of microbial threats the FDA has been tracking with increasing intensity across the tattoo ink supply chain: organisms that, in a normal environment, pose limited danger, but become genuinely serious when injected into the dermis. The compounding problem is that early-stage symptoms, swelling, localized redness, and inflammation, can look almost identical to a standard allergic reaction. That overlap delays diagnosis and complicates treatment.

For geometric and dotwork artists, a yellow pigment recall has operational consequences beyond the safety concern. Saturated warm tones are common in color-fill accents and geometric compositions, particularly when artists are building contrast across multi-session work. If Golden Yellow from this batch was part of an ongoing series of appointments, the choice is either delay the next session while sourcing a verified clean replacement or find that replacement before the next client sits down. Either way, visual consistency takes a hit mid-process.

The immediate step is to pull every bottle of Golden Yellow with a batch date of 8/22/2025 and quarantine it. Not shelved separately, actually quarantined and removed from rotation. Contact your supplier for a replacement and get documentation in writing. If the lot number of product used on recent clients cannot be confirmed, those clients should be contacted directly.

The symptoms to monitor for in the weeks following a session: persistent swelling that does not resolve, spreading redness beyond the tattoo border, fever, or purulent drainage. Any of those warrant a medical visit, and the provider treating the client needs the product name and batch information to treat it properly.

The broader supply-chain reality this recall exposes is that tattoo inks operate in a regulatory environment where lot-level traceability frequently depends on the artist, not the manufacturer. This recall arrived inside a digest notice, not as a targeted alert to studios or distributors. That means plenty of artists may have the bottle in their cabinet right now without knowing it was flagged.

The fix is a studio record habit: log lot numbers against every client session, demand batch documentation before every ink order, and prioritize vendors who publish quality-control data. When recalls like this one surface, that habit compresses the response from a client notification crisis down to a five-minute inventory check.